The online version of this article (doi:10.1186/1471-2296-15-8) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
PKTL/ KK/ AL conceptualised the whole study. KK researched data and wrote the manuscript. KMC, EMTH, ML, SYL and AL reviewed the manuscript. CCS/PKTL contributed to results/discussion and reviewed the manuscript. All authors declare that there are no financial relationships with any organisations that might have an interest in the submitted work, and that no presentations have been made for this research. All authors read and approved the final manuscript.
A territory-wide diabetes management program (Risk Assessment Management Program – RAMP) was recently established, providing comprehensive management for all diabetics, helping to delineate current level of control and complications prevalence among primary care diabetic patients in Hong Kong.
This cross-sectional study captured anonymous clinical data from RAMP patients. Data obtained include sociodemographic details, type of diabetes, illness duration, family history, drug usage, coexisting illnesses, diabetic complications and other clinical parameters.
Data from 15,856 type 2 diabetic patients were analyzed. 57.1% were above 60 years old, with mean disease duration of 7.3 years. Hypertension was the commonest coexisting chronic illness (57.6%). 30.2% and 61.8% have their systolic and diastolic pressure controlled to below 130 mmHg and 80 mmHg respectively. Over half (51.5%) had an HbA1c level of less than 7.0%. 88.4% did not achieve target lipid level. 15% were on diet control alone. Only 22.2% were on statins. In patients with microalbuminuria and macroalbuminuria, 40.7% and 54.5% were on angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) respectively. 12.9%, 38.8% and 2.4% had diabetic retinopathy, nephropathy and neuropathy respectively. Overall, 37.9%, 7.3% and 0.4% had single, two and three concurrent microvascular complications respectively.
The level of diabetic control is comparable with other developed countries. We demonstrated a high prevalence of microvascular complications among Chinese primary care patients despite achieving adequate HbA1c levels, highlighting the importance of managing all aspects of diabetes including weight, lipid and blood pressure. Efforts to improve holistic management must be tailored according to the needs of our population, with the challenges that the majority have low educational background and in the older age group.
World Health Organisation: Diabetes Programme. 2012, http://www.who.int/diabetes/en/,
International Diabetes Federation: The Global Burden. In Diabetes Atlas. 2012, http://www.idf.org/sites/default/files/The_Global_Burden.pdf,
Wong MC, Sin CK, Lee JP: The reference framework for diabetes care in primary care settings. Hong Kong Med J. 2012, 18: 238-246. PubMed
Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
The Information Centre, NHS: National Diabetes Audit Executive Summary 2009–2010. National Diabetes Audit. 2011, http://www.hqip.org.uk/assets/NCAPOP-Library/National-Diabetes-Audit-Executive-Summary-2009-2010.pdf,
Wong MC, Jiang JY, Gibbs T, Griffiths SM: Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. A J Hypertens. 2009, 22: 802-810. 10.1038/ajh.2009.67. CrossRef
Wing RR: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010, 170: 1566-1575. PubMed
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004, 364: 685-696. 10.1016/S0140-6736(04)16895-5. CrossRefPubMed
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22. CrossRef
Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, et al: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002, 105: 1424-1428. 10.1161/01.CIR.0000012918.84068.43. CrossRefPubMed
Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T: Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications. 2012, 26: 123-128. 10.1016/j.jdiacomp.2012.02.001. CrossRefPubMed
So WY, Raboca J, Sobrepena L, Yoon KH, Deerochanawong C, Ho LT, Himathongkam T, Tong P, Lyubomirsky G, Ko G, Nan H, Chan J, JADE Program Research Team: Comprehensive risk assessments of diabetic patients from seven Asian countries: The Joint Asia Diabetes Evaluation (JADE) program. J Diabetes. 2011, 3: 109-118. 10.1111/j.1753-0407.2011.00115.x. CrossRefPubMed
Lu B, Hu J, Wen J, Zhang Z, Zhou L, Li Y, Hu R: Deterimination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-diabetes - ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SH-DREAMS). PLoS One. 2013, 8: e61053-10.1371/journal.pone.0061053. CrossRefPubMedPubMedCentral
- Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study
Kai Ming Chow
Eric Ming-Tung Hui
Shuk Yun Leung
Cheuk Chun Szeto
Philip Kam-Tao Li
- BioMed Central
Neu im Fachgebiet Allgemeinmedizin
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II